Skip to content

Clinical research of transplantation of functional scaffold seeded with mesenchymal stem cells for the treatment of traumatic spinal cord injury

Clinical research of transplantation of functional scaffold seeded with mesenchymal stem cells for the treatment of traumatic spinal cord injury

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012152
Enrollment
Unknown
Registered
2017-07-26
Start date
2017-09-30
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal cord injury

Interventions

functional scaffold only:transplantation of functional scaffold only
functional scaffold seeded with low dose of mesenchymal stem cells:transplantation of functional scaffold seeded with low dose of mesenchymal stem cells
functional scaffold seeded with moderate dose of mesenchymal stem cells:transplantation of functional scaffold seeded with moderate dose of mesenchymal stem cells
functional scaffold seeded with high dose of mesenchymal stem cells:transplantation of functional scaffold seeded with high dose of mesenchymal stem cells

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. T1-11complete spinal cord injury (ASIA spinal cord injury assessment grade A, proved by electrophysiology test and MRI, injury level will be confirmed by physical examination); 2. The glial scar after spinal cord injury less than 2cm (proved by MRI); 3. Male or female aged 18-60 years with acute or subacute spinal cord injury (less than 3 months, ASIA grade A), no improvement after rehabilitation training; 4. Good muscle condition, function of peripheral nerves should be normal; 5. Good general condition,function of major organs should be normal; major laboratory examinations should be normal; 6. No brain diseases or psychological diseases; 7. Good compliance and knowledge level, have an objective understanding to the condition and prognosis of the disease.

Exclusion criteria

Exclusion criteria: 1. Combined with diseases that affect the recovery of spinal cord injury or rehabilitation training; 2. Non thoracic spinal cord injury; 3. Incomplete spinal cord injury or undefined injury site and range; 4. No rehabilitation training after spinal cord injury; 5. Muscle atrophy or fibrosis; 6. Degeneration of peripheral nerve; 7. Allergic constitution; 8. Received immunomodulator or experimental drug treatment 60 days before the research; 9. Severe background diseases, diabetes, autoimmune diseases, tumor or severe high blood pressure; 10. Poor general condition, malfunction of major organs, intolerance of surgery; 11. MODS, sepsis associated organ failure assessment score=12; 12. Routine laboratory examinations inadequate and at least 1 positive result of the blood test: HCV antibody, HIV antibody or HTLV-1 antibody; 13. Severe bleeding tendency or coagulation disorders; 14. surgical site inflammation or skin ulcer; 15. Pregnancy or lactation period; 16. Refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
vital signs;blood routine examination;blood biochemistry examination;urine routine examination;blood coagulation examination;urinary sediment examination;stool OB examination;syphilis test;ECG;chest X-ray examination;psychological test;ASIA spinal cord injury assesment;motor score of key muncles;sensory score of key sites;function independent measure;electromyography;electrophysiology;MRI examination;urodynamic test;spasm;pain;gene analysis of blood sample;immune factors test of blood sample;

Countries

China

Contacts

Public ContactLiming Cheng

Shanghai Tongji Hospital

chlm.d@163.com+86 13701959550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026